Close Menu

MADRID (360Dx) – Becton Dickinson over the weekend provided a roadmap for its molecular diagnostics and microbiology laboratory businesses with the unveiling of several soon-to-be launched products.

At the European Congress of Clinical Microbiology and Infectious Diseases held here, BD introduced its first new molecular testing platform in several years, the BD Cor, a fully automated high-throughput, real-time PCR testing system expected to launch next year in Europe and compete with the likes of similar platforms offered by Roche, Abbott, and Hologic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.